Metabolic syndrome in Chinese patients with systemic lupus erythematosus: No association with plasma cortisol level

Lupus

Volumn 22, Issue 5, 2013, Pages 519-526

  Liu, S Y ^a   Han, L S ^a   Guo, J Y ^a   Zheng, Z H ^a   Li, H ^a   Zhang, L ^a   Zhang, X ^a   He, Y J ^a   Gao, G M ^a   Liu, Z S ^a   Zeng, X F ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

cortisol; hydroxychloroquine; metabolic syndrome; prednisone; systemic lupus erythematosus

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; HYDROXYCHLOROQUINE; INSULIN;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CASE-CONTROL STUDIES; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROCORTISONE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84875963554     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313478301     Document Type: Article

References (44)

1. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association/National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 ; 112: 2735-2752
2. Grundy SM. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006 ; 47: 1093-1100
3. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation. 2004 ; 109: 706-713
4. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 ; 117: e25 - e146
5. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006 ; 95: 136-147
6. Janus ED. Metabolic syndrome and its relevance to Asia. International Congress Series. 2004 ; 1262: 535-537
7. Chung CP, Ingrid Avalos, Annette Oeser, et al. High prevalence of metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characters and cardiovascular risk factors. Ann Rheum Dis. 2007 ; 66: 208-214
8. Wannamethee SG, Gordon DOL, Shaper AG, et al. The metabolic syndrome and insulin resistance: Relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis. 2005 ; 181: 101-108
9. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2407-2415
10. Bruce IN. "Not only...but also": Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. 2005 ; 44: 1492-1502
11. Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005 ; 14: 683-686
12. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum. 2003 ; 48: 3159-3167
13. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fall to account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 ; 44: 2331-2337
14. Mok CC, Poon WL, Lai JP, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010 ; 39: 38-41
15. Bellomio V, Splindler A, Lucero E, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009 ; 18: 1019-1025
16. Negrón AM, Molina MJ, Mayor AM, et al. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008 ; 17: 348-354
17. El Magadmi M, Ahmad Y, Turkie W, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006 ; 33: 50-56
18. Bultink IE, Turkstra F, Diamant M, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol. 2008 ; 26: 32-38
19. Sabio JM, Zamora-Posadas M, Jiménez-Jáimez J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus. 2008 ; 17: 849-859
20. Walker BR, Phillips DIW, Noon JP, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension. 1998 ; 31: 891-895
21. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: Relationships with abdominal obesity and endocrine, metabolic and haemodynamic abnormalities. J Clin Endocrinol Metab. 1998 ; 83: 1853-1859
22. Zietz B, Reber T, Oertel M, et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol. 2000 ; 27: 911-918
23. Straub RH, Weidler C, Demmel B, et al. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2004 ; 63: 961-968
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
26. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120: 1640-1645
27. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus. 1997 ; 6: 533-539
28. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function?. J Physiol Pharmacol. 2006 ; 57: 505-528
29. Whitehead JP, Richards AA, Hickman U, a1. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006 ; 8: 264-280
30. Chung CP, Long AG, Solus JF, a1. Adipocytokines in systemic lupus erythematosus: relationship with inflammation, insulin resistance and coronary atherosclerosis. Lupus. 2009 ; 18: 799-806
31. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2399-2406
32. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, a1. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis. 2010 ; 69: 20-28
33. Petri M, Ferrnan D, Goldman D, et al. Hypoglycemic effect of hydroxychloroquine in systemic lupus erythematosus. Arthritis Rheum. 1994 ; 37: R24 - R24
34. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am J Med. 1990 ; 89: 322-326
35. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001 ; 28: 780-785
36. Bevan AP, Krook A, Tikerpae J, Seabright PJ, Siddle K, Smith GD. Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes. J Biol Chem. 1997 ; 272: 26833-26840
37. Reilly MP, Wolfe ML, Rhodes T, et al. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 2004 ; 110: 803-809
38. Richard SB. Type 2 diabetes: Multiple treatments for a multicomponent condition. In: Richard S. Beaser and the staff of Joslin Diabetes Center (eds) Joslin's diabetes deskbook: A guide for primary care providers. 2nd ed. Lippincott: Williams & Wilkins, 2007, pp.153-170.
39. Straub RH, Pongratz G, Schölmerich J, et al. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. Arthritis Rheum. 2003 ; 48: 1504-1512
40. Straub RH, Paimela L, Peltomaa R, et al. Inadequately low serum levels of steroid hormones in relation to IL-6 and TNF in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 2002 ; 46: 654-662
41. Straub RH, Weidler C, Demmel B, et al. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2004 ; 63: 961-968
42. Jamieson PM, Chapman KE, Edwards CR, et al. 11b-hydroxysteroid dehydrogenase is an exclusive 11b-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology. 1995 ; 136 (11). 4754-4761
43. Reynolds RM, Walker BR, Syddall HE, et al. Elevated plasma cortisol in glucose intolerant men: Differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab. 2001 ; 86: 1149-1153
44. Gibson EL, Checkley S, Papadopoulos A, et al. Increased salivary cortisol reliably induced by a protein-rich midday meal. Psychosom Med. 1999 ; 61: 214-224